Overview

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborator:
Gynecologic Oncology Group
Treatments:
Thalidomide